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A study by Chemtob and co-workers found significantly lower prevalence of HIV amongst heterosexual men and
women in Israel compared with the Netherlands and France. Risk factors for heterosexual HIV infection in these
countries were similar, apart from one, namely, a strikingly higher prevalence of male circumcision (MC) in Israel
compared with the Netherlands and France. It is now well established that MC protects heterosexual men against
becoming infected with HIV during sexual intercourse with an infected woman. In epidemic settings, such as
countries in sub-Saharan Africa, in which heterosexual contact is the primary driver for HIV infection, MC is being
implemented to reduce HIV prevalence. The results of the new study by Chemtob and co-workers support the
evidence and recent polices in the United States advocating MC to reduce the spread of HIV. While prevalence in
developed countries is generally low, it is rising. In the long term, neonatal MC is the most desirable option, since
not only is it simpler, safer, cheaper and more convenient than MC later, it provides immediate protection from
infections, penile inflammation, genital cancers and physical problems. It is also cost-effective. European countries
have not supported MC for its public health benefits. The new findings add to calls for European and other countries
with low MC prevalence to consider developing evidence-based policies favoring MC in order to reduce HIV and other
infections and diseases and at the same time reduce suffering, mortality and the cost of treating these.
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The evidence that male circumcision (MC) can substan-
tially reduce HIV infection in men during heterosexual
intercourse is now well accepted, leading to its adoption
as an HIV prevention strategy in high prevalence set-
tings of sub-Saharan Africa [1]. The policy followed the
publication of results from three randomized controlled
trials (RCTs) in South Africa [2], Kenya [3] and Uganda
[4]. Further support has been provided by meta-analyses
[5–8], effectiveness studies in the implementation of MC
[9], follow-up of RCT study participants in which protec-
tion reached 70 % [10–12], and biological evidence [13].
However, the relevance of MC for HIV prevention in
low prevalence settings, as applies to developed nations,
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A recent article in Israel Journal of Health Policy Research
by Chemtob and colleagues has provided much-needed
evidence demonstrating that MC was associated with re-
duced HIV acquisition in heterosexuals in countries in
which HIV prevalence is low [14]. The study found the
rate of newly diagnosed heterosexual HIV cases in Israel,
where MC prevalence exceeds 90 %, was 0.46 (range
0.26–0.70) per 100,000 of the population per year over the
period 2004–2010. The annual incidence of HIV infection
in men in Israel was on average 6 times lower than in the
Netherlands (mean 2.0 annual cases per 100,000 of the
population; range 1.9–2.3) and France (mean 3.3; range
2.7–3.5) where the MC prevalence in both is less than
10 %. HIV prevalence was also lower in women in Israel
(0.20; range 0.10–0.34), where the number of cases per
year were 10 times fewer over that period when compared
with the annual number of cases in women in the
Netherlands (1.4; range 1.1–2.1) and France (2.6; rangeccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Morris and Klausner Israel Journal of Health Policy Research  (2015) 4:40 Page 2 of 42.4–3.1). The authors excluded cases originating in men
who have sex with men and intravenous drug users, each
of which represent high-risk groups. In addition, they also
excluded cases of heterosexual HIV transmission originat-
ing from countries with generalized HIV epidemics. Mi-
grants were, moreover, unlikely to contribute very much
to HIV infections in the general heterosexual populations
of each country.
While inter-country comparisons are subject to the in-
fluence of confounding factors, including sexual behav-
ior, the three countries examined are fairly similar in just
about every aspect of known risk factors for sexually ac-
quired HIV infection, apart from MC prevalence. Those
factors included the number of sex partners and condom
use. The proportion of people tested for HIV in the past
year was highest in Israel. The authors suggest that in-
fection of women by a small proportion of men who en-
gage in sexual intercourse with both women and other
men was of very limited impact.
HIV was once a rare virus
In those countries, mostly in sub-Saharan Africa, where
HIV prevalence is at epidemic levels, HIV was once rare
or nonexistent. Had MC been introduced as a preventive
measure before the three trials were completed in 2007
then many infections would have been averted and lives
could have been saved [15].
HIV is rising in developed countries
In confirmation of the basis of the findings by Chemtob
et al., the protective effect of MC against acquisition of
HIV in heterosexual men applies just as well in another
low prevalence country, the USA [16]. The proportion
of HIV cases attributable to heterosexual contact has,
moreover, risen substantially with time in developed
countries [17, 18]. National statistics for Australia show
that 25 % of cases involved heterosexual contact [18].
After excluding cases from a high prevalence country,
the number of cases whose exposure to HIV was attrib-
uted to heterosexual contact has increased by 28 % over
the past decade [18], 29 % of these being in individ-
uals born in Australia [18, 19]. There has been a
steady rise in HIV prevalence in the WHO European
Region [20], notably in some non-drug injecting, het-
erosexual populations in Eastern Europe, as well as in
Central Asia [21]. In African Americans in the USA,
HIV rates are rising faster than almost all other
groups in that country [22]. The US Centers for Dis-
ease Control and Prevention (CDC) has recom-
mended MC for HIV prevention in high prevalence
groups such as those [23]. Protection against HIV in-
fection was an important component of recent MC
policy recommendations by the US CDC [24] and the
American Academy of Pediatrics [25].The looming treatment burden
A recent study in the Netherlands highlighted the loom-
ing medical burden as a result of an anticipated enormous
increase in multiple morbidities and drug interactions in
aging HIV-infected patients on combination antiretroviral
therapy [26].
Neonatal circumcision preferable
In the long term, neonatal MC appears to offer advan-
tages over adult MC for prophylaxis against HIV and
other infectious diseases globally [27]. That is because
neonatal MC is cheaper, simpler, safer, more convenient,
averts concerns about premature resumption of sex dur-
ing wound healing and provides a risk-benefit ratio of
100:1 in favor [28], as noted by the US CDC [24]. Ad-
verse events are uncommon, virtually all being minor,
easy to treat and with complete resolution [25, 28, 29].
Effectiveness against HIV
The 60 % or higher efficacy of MC in protecting heterosex-
ual men against HIV infection [5, 9–12] makes MC more
effective than condoms. That is because, even though
condoms are 80 % protective against HIV infection if used
consistently and correctly [30, 31], a Cochrane systematic
review of RCTs of condom use found, “little clinical evi-
dence of effectiveness” and no “favorable results” for HIV
prevention [32]. Unlike condoms, MC is a one-off proced-
ure that does not require an item to be applied or adminis-
tered each time a man has sexual intercourse. Nevertheless
both MC and condom use should be advocated.
By reducing HIV prevalence in heterosexual men, MC
will help reduce HIV prevalence in women [33] and chil-
dren [34]. It will also help lower risks for other sexually
transmitted infections [28, 35–58], including those that
exacerbate HIV risk [41–44].
Finally, MC has been shown to be the most cost-
effective of all the available interventions for HIV pre-
vention [59]. Calculations for the US have shown that
if MC prevalence were to fall from the current high
levels of 80 to 10 %, as typically seen in Europe, dir-
ect costs for treatment of urinary tract and sexually
transmitted infections, including HIV, would increase
by US$4.4 billion for 10 annual birth cohorts [60].
Conclusion
The new findings by Chemtob et al. have broad implica-
tions for efforts to arrest the continued spread of HIV in
the heterosexual community of developed countries in
which HIV prevalence is currently low. While routine
MC will be easier in countries such as Israel and the US
that already enjoy a cultural or religious tradition of in-
fant MC, it presents a challenge in countries such as
those in Europe in which a cultural bias against MC ex-
ists amongst the majority [61].
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